In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 + T cell responses
Journal for ImmunoTherapy of Cancer · 2025-12 · 13 (12) · e011665
DOI: 10.1136/jitc-2025-011665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 12.12.2025. Verfasst von Mengjiao Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, People's Republic of China. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Receptor Superfamily, Member 9, CD8-Positive T-Lymphocytes, Dendritic Cells, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Intratumoral vaccines offer a promising avenue in cancer immunotherapy by harnessing the tumor microenvironment to stimulate immune responses. However, challenges persist in maximizing their effectiveness and addressing immune suppression within tumors.
Methods
Conventional in situ vaccine (CisVac) and α-CD137 antibody were administered in implanted mouse models of lung and colon cancer to evaluate therapeutic efficacy. The initiation mechanism of CD8 + T cells was determined using antibody blockade and transgenic mouse models. Single-cell RNA sequencing was used to further characterize the activation mechanism of T cells.
Results
Our findings indicate that this synergistic approach markedly inhibits tumor growth while eliciting a robust antitumor immune response, characterized by heightened activation and cytotoxic differentiation of CD8 + T cells, as well as the polarization of conventional dendritic cells (cDC1). Mechanistically, it promotes the cDC1-dependent proportion and cytokine production of tumor antigen-specific CD8 + T cells, mobilizes and establishes enduring systemic immune memory. Our single-cell transcriptome analyses revealed that the therapy facilitates a functional remodeling of regulatory T cells (Tregs) with upregulated inflammatory genes, potentially attenuating immune suppression. Cell–cell communication analyses highlighted interactions between CD4 + Th1-like/Th17 cells and monocytes/DCs through the CD40L-CD40 pathway, indicating potential intercellular regulatory mechanisms.
Conclusions
Our results highlight the transformative potential of the CisVac/α-CD137 combination in cancer immunotherapy, paving the way for further exploration of its clinical utility and long-term efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, People's Republic of China.
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital,…
- Institute of Modern Biology, Nanjing University, Nanjing, Jiangsu, People's Republic of China.
- Department of Thoracic Surgery, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health…
- State Key Laboratory of Respiratory Disease, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
- Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy &Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, De…
Zitieren
APA
Wang, M., Qiu, L., Tang, C., Huang, D., Zheng, Q., Li, Z., Zhang, Z., Wei, S., Chen, L., Huang, H., Liu, J., Zhou, J., Lu, T., Liu, G., Nie, Y., Leng, Q., & Chen, T. (2025). In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 + T cell responses. Journal for ImmunoTherapy of Cancer, 13(12), e011665. https://doi.org/10.1136/jitc-2025-011665
Vancouver
Wang M, Qiu L, Tang C, Huang D, Zheng Q, Li Z, et al. In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 + T cell responses. Journal for ImmunoTherapy of Cancer. 2025;13(12):e011665. doi:10.1136/jitc-2025-011665
BibTeX
@article{Wang2025,
author = {Wang, Mengjiao and Qiu, Li and Tang, Cheng and Huang, Danqing and Zheng, Qiaocong and Li, Zunyi and Zhang, Zhenhui and Wei, Shupei and Chen, Lanfang and Huang, Hongxin and Liu, Jun and Zhou, Junfeng and Lu, Tao and Liu, Guanxin and Nie, Yingjie and Leng, Qibin and Chen, Tao},
title = {In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 + T cell responses},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {12},
pages = {e011665},
doi = {10.1136/jitc-2025-011665}
}
EUVIMED